ClinicalTrials.gg
CompletedNCT06092762Updated Nov 25, 2024

A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of AK120 in Atopic Dermatitis, sponsored by Akeso. Completed at 26 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
86th of 190
180 · median 164
Started
2023
with 38 others
Phase 2
58 of 206
16 open now
Registered
90th of 206
by date
Lead sponsor
6 of 206
Akeso

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 86th largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 58 in phase 2, and was the 90th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open label phase II clinical study to evaluate the safety and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

Read the detailed description

This is a multicenter, randomized, open label phase II clinical study to evaluate the safety and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis. The total duration of the study (including screening period) planned for each subject is approximately 29 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥18≤75 years old.
  2. Atopic dermatitis (AD) diagnosed at least half a year before screening.
  3. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.
  4. Subjects with a history of an inadequate response or medically inappropriate use of topical drug treatment within 6 months

Exclusion criteria

Exclusion Criteria:

  1. Received systemic , /immunomodulatory drugs, phototherapy within the 4 weeks before randomization.
  2. Received systemic traditional Chinese medicine treatment within the 4 weeks before randomization or topical traditional Chinese medicine treatment within 1 week before randomization
  3. Received treatment with other clinical study drugs within 1 month or 5 half-lives before randomization (whichever is longer)
  4. Received or planned to receive treatment within the 3 months before randomization or during the study period.
  5. Received allergen specific immunotherapy within the 3 months before randomization.
  6. Have a history of allergies to any component of AK120 and/or severe allergic reactions to monoclonal antibodies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    AK120 300mg

    AK120 loading dose 600mg, then 300mg subcutaneous injection every 2 weeks thereafter until week 14.

    Drug: AK120

  • Experimental
    AK120 450mg

    AK120 loading dose 600mg, then 450mg subcutaneous injection every 2 weeks thereafter until week 14.

    Drug: AK120

Interventions

  • DrugAK120

    subcutaneous injection every 2 weeks

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events(AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: week 0 to week 24

Secondary outcomes

  1. Percentage of subjects who achieved (Eczema Area and Severity Index) EASI-75

    Time frame: at week 2/4/8/12/16 /20 and 24

  2. Percentage of subjects who achieved (Eczema Area and Severity Index) EASI-50

    Time frame: at week 2/4/8/12/16 /20 and 24

  3. Percentage change in (Eczema Area and Severity Index) EASI scores from baseline

    Time frame: at week 2/4/8/12/16 /20 and 24

  4. Percentage of subjects who achieved 0/1 in the (Investigator's Global Assessment) IGA

    Time frame: at week 2/4/8/12/16 /20 and 24

  5. Percentage of subjects with a (Investigator's Global Assessment) IGA score decrease of ≥ 2 points from baseline

    Time frame: at week 2/4/8/12/16 /20 and 24

  6. Percentage change in (affected body surface area) BSA score from baseline

    Time frame: at week 2/4/8/12/16 /20 and 24

07

Study locations

26 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Air Force Medical Center
    Beijing, Beijing, China
  • China-Japan Friendship Hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian, China
  • Dongguan People's Hospital
    Dongguan, Guangdong, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • People Hospital of Xingtai
    Xingtai, Hebei, China
  • Renmin Hospital of Wuhan University Hubei General Hospital
    Wuhan, Hubei, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
  • Yancheng No.1 People's Hospital
    Yancheng, Jiangsu, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia, China
  • Qingdao Municipal Hospital
    Qingdao, Shandong, China
  • Baoji Central Hospital
    Baoji, Shanxi, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Taiyuan Central Hospital
    Taiyuan, Shanxi, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin, China
  • The First Affiliated Hospital,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Ningbo No.2 Hospital
    Ningbo, Zhejiang, China
  • The first affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    Yiwu, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Nov 2024, 12 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartActual
Nov 6, 2023
Primary completionActual
Nov 13, 2024
CompletionActual
Nov 13, 2024
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06092762
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Nov 6, 2023
Primary completion
Nov 13, 2024
Completion
Nov 13, 2024
Last update
Nov 25, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion